|
Today's Headlines
FDA has eased restrictions on patient access to the controversial diabetes drug rosiglitazone (Avandia, GlaxoSmithKline). The agency made its determination after an FDA Advisory Committee reviewed the drug in June 2013 and voted to lift its restrictions, and new information was released indicating that the drug carries no heightened cardiovascular risk. » Full article
|
|
FDA has simeprevir (Olysio, Janssen Therapeutics, Division of Janssen Products, LP) for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. » Full article
|
|
FDA is warning healthcare professionals of the rare but serious risk of heart attack and death with use of cardiac nuclear stress test agents regadenoson (Lexiscan) and adenosine (Adenoscan).
» Full article
|
|
FDA approved the first adjuvanted vaccine for the prevention of H5N1 influenza, commonly known as avian or bird flu. The vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, is for use in people aged 18 years and older who are at increased risk of exposure to the H5N1 influenza virus. » Full article
|
Continuing Education
This month, Drug Topics offers the first of a two-part CPE series, "MTM considerations in multiple sclerosis." Earn up to 2 credits by completing this knowledge-based activity. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
|
EDITOR'S PICK
Listen to Eliav Barr, MD, vice president, infectious disease project and pipeline lead at Merck Research Laboratories in West Point, Pa., discuss with Formulary the cost burden of hepatitis C to the healthcare system, what to expect in the hepatitis pipeline in the near future, and the most effective way to manage these drugs on the formulary.
» Full article
|
|
Like
Tweet
